Post by
Riverfolk on Feb 14, 2021 2:17pm
Post Covid Potential of 5-15 billion annual Revenue
“But if (Metablok) is found to be useful in a situation like COVID, it could be useful in many other situations that will continue to occur even when the pandemic is over. So it’s got potential well beyond COVID, which is another great reason we were interested in helping out with the trial.”
Kidney - 5 billion
lung - 8-10 billion
liver - TBD
Comment by
2019champs on Feb 14, 2021 5:27pm
The kidney is 5 billion with no competition. Then you have the lung and the liver. Lets be extremely generous here and say this drug is worth 2B. That puts as at $30 share price. Again that is being extremely generous.